Kyongbo Pharmaceutical Co Ltd Capital Reinvestment Ratio
Kyongbo Pharmaceutical Co Ltd capital reinvestment ratio. Kyongbo Pharmaceutical Co Ltd (214390) has a Capital Reinvestment Ratio of 8.69x as of March 2026, meaning it reinvests 9% of its operating cash flow (₩1.79 Billion) in capital expenditures (₩15.55 Billion). Check 214390 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Kyongbo Pharmaceutical Co Ltd (2014–2025)
Capital reinvestment ratio of Kyongbo Pharmaceutical Co Ltd from 2014 to 2025. This chart tracks Kyongbo Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 11 annual periods. Also explore Kyongbo Pharmaceutical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Kyongbo Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2014–2025)
Kyongbo Pharmaceutical Co Ltd capital reinvestment ratio by year from 2014 to 2025. For the full cash flow conversion analysis, see cash efficiency ratio of Kyongbo Pharmaceutical Co Ltd.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 5.58x | ₩7.46 Billion | ₩41.61 Billion | ▼ -93.7% |
| 2024 | 88.35x | ₩149.12 Million | ₩13.18 Billion | ▲ +3835.0% |
| 2023 | 2.25x | ₩4.84 Billion | ₩10.88 Billion | ▲ +72.5% |
| 2022 | 1.30x | ₩10.13 Billion | ₩13.18 Billion | ▲ +27.7% |
| 2021 | 1.02x | ₩17.97 Billion | ₩18.32 Billion | ▲ +70.5% |
| 2020 | 0.60x | ₩20.80 Billion | ₩12.44 Billion | ▼ -39.1% |
| 2019 | 0.98x | ₩23.67 Billion | ₩23.25 Billion | ▲ +242.7% |
| 2017 | 0.29x | ₩25.81 Billion | ₩7.40 Billion | ▼ -63.1% |
| 2016 | 0.78x | ₩25.33 Billion | ₩19.68 Billion | ▼ -87.9% |
| 2015 | 6.43x | ₩4.24 Billion | ₩27.26 Billion | ▲ +434.9% |
| 2014 | 1.20x | ₩16.04 Billion | ₩19.28 Billion | — |